Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent (NYSE:A) reported second-quarter fiscal 2026 revenue of $1.83 billion, up 10.0% reported and 6.3% core year-over-year. GAAP EPS was $1.20 and non-GAAP EPS $1.49, rising 60% and 14% respectively.
The company raised fiscal 2026 guidance, now expecting revenue of $7.39–$7.49 billion and non-GAAP EPS of $6.00–$6.10. Q2 non-GAAP operating margin reached 26.4%, with all three business groups delivering reported revenue growth of 6–14%.
Agilent (NYSE:A) launched a new multi-attribute method (MAM) LC/HRMS workflow for pharmaceutical and biopharmaceutical quality control laboratories. The solution combines software, instruments, columns, consumables, and standards to support routine, regulated testing and monitoring of critical quality attributes in late-stage development and commercial manufacturing.
The workflow integrates with OpenLab CDS to support method transfer from R&D into manufacturing and is available globally. Agilent reports fiscal 2025 revenue of $6.95 billion and a workforce of about 18,000 worldwide.
Agilent (NYSE:A) launched its 8890B GC and 8860B GC systems featuring GC Assist, an integrated intelligence platform for system monitoring, diagnostics, and remote connectivity. The instruments aim to reduce downtime, improve data quality, and boost laboratory efficiency and throughput through faster oven cooling, added detector capacity, and guided maintenance.
GC Assist supports continuous performance monitoring, quality control alerts, and maintenance guidance. The systems are introduced globally and backed by Agilent’s worldwide sales, service, and application teams. Agilent reported $6.95 billion in fiscal 2025 revenue and employs about 18,000 people.
Agilent (NYSE:A) launched the 9500 Triple Quadrupole ICP-MS, a next-generation inductively coupled plasma mass spectrometry system aimed at labs moving from single to triple quadrupole technology.
The 9500 offers over 33% typical reduction in acquisition time, advanced interference removal via Air Cell and Advanced Helium Mode using the Dual-Cell System, and integration with OpenLab ICP-MS software. It targets environmental, food, pharma, chemical, materials, and contract testing labs, aiming to boost productivity, reduce reruns, and lessen reliance on oxygen cylinders.
Agilent (NYSE:A) launched the 1290 Infinity III Fluorescence Detector, a fluorescence detector optimized for modern UHPLC workflows. It combines ultra-trace sensitivity, UHPLC-ready chromatographic performance, and ease of use for standalone operation or in-line LC/MS setups.
The detector preserves narrow UHPLC peak integrity while delivering rich spectral information, supporting trace-level analysis in biopharma, food safety, and environmental applications.
Agilent (NYSE:A) declared a quarterly cash dividend of $0.255 per share of common stock. The dividend is payable on July 22, 2026 to shareholders of record as of June 30, 2026. Agilent reported $6.95 billion in fiscal 2025 revenue and employs about 18,000 people worldwide.
Agilent (NYSE:A) announced a TSA contract to deploy its new Bulk Alarm Resolution Technology (BRT) at U.S. airport security checkpoints in FIFA World Cup 2026 host cities.
The BRT uses Surface Offset Raman Spectroscopy and algorithms to quickly confirm liquids, gels, creams, solids, and powders through various containers, aiming to enhance detection, efficiency, and traveler experience.
Agilent (NYSE:A) will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, at 9:20 a.m. EDT in New York City.
A live audio webcast and replay will be available on Agilent’s investor relations website. Agilent reported $6.95 billion fiscal 2025 revenue and employs about 18,000 people.
Agilent (NYSE: A) named Michael Buckner as chief legal officer, effective May 4, 2026. Buckner brings nearly three decades of senior global legal experience across mergers and acquisitions, antitrust, intellectual property and regulatory matters.
He joins from Danaher, where he led M&A legal strategy including the Abcam acquisition and Veralto spin-off. Agilent reported fiscal 2025 revenue of $6.95 billion and about 18,000 employees.
Agilent (NYSE: A) will report second-quarter fiscal 2026 results after the market close on May 27, 2026 and will host a listen-only conference call webcast at 1:30 p.m. PDT the same day. A recording will be available on the investor website for 90 days.
Agilent reported $6.95 billion revenue for fiscal 2025 and employs about 18,000 people worldwide. Webcast access is via the Events section of Agilent's Investor Relations site.